Dear Reader,
A little-known research company has come up with the biggest advance in medicine in the last 150 years.
Bigger than the invention of X-rays in 1895… the discovery of penicillin in 1928… even the development of chemotherapy in 1942.
Yet surprisingly, it’s not a drug… surgical tool… new cancer treatment… nor anything else you might expect.
Rather, it involves stunning technology that accurately designs new drugs to treat or even cure – many of the world’s most dreaded diseases.
Better yet, it then lays out a blueprint for how to create these new drugs on a mass scale.
We call it “Cures on Demand”…
And the ramifications of this medical breakthrough are, in a word, staggering.
Imagine a world where drug companies can eliminate years of painstaking research to develop a new cancer treatment… cholesterol medicine… or anti-inflammatory pill.
They simply use this technology and almost instantly find out the best new drug candidates.
I know that sounds crazy, but it’s happening right now.
It’s a completely new paradigm for the entire $956 billion a year pharmaceutical industry.
And if this situation plays out as we anticipate, it could lead to the single biggest gains of any investment we’ve recommended in our 25-year history.
A Northwestern University professor recently reported on the effects of just one of these new “Cures on Demand” compounds – in this case, a multiple sclerosis-fighting drug.
He called the results “quite dramatic” and “long-lasting”.
And that’s just one of the many cures this innovation stands to create in the days ahead…
This “Cures on Demand” technology could soon send dozens, even hundreds of diseases, conditions, and maladies straight into the medical history books.
In other words, it’s the mother of all drug breakthroughs.
And here’s the thing…
We’ve been closely tracking the one tiny company behind this story for over three years.
We’ve talked directly with its executives. We’ve watched as they perfected their Cures on Demand technology.
And we’ve waited for the ideal time to get in: After all the stars aligned perfectly for this company… But before the details became public knowledge.
That time is now.
In the next few months, other investors will start hearing about this medical revolution in business magazines and on financial websites.
Millions more of the sick and the elderly will be clamoring for these miraculous new breakthroughs.
But you’ll already know the full story… and be in position to profit massively.
I’ll tell you everything you need to know in just a moment.
But first, let me reveal just how much money you could make if this Cures on Demand situation pays off as we expect.
$25,000 in Four Weeks…
Practically everyone knows that health and biotech breakthroughs can hand investors some of the biggest gains of their lives.
The key, of course, is getting into a great company, and doing it well ahead of the crowd.
Once you’re hearing about a firm in The Wall Street Journal or on CNBC, the price has already run up, and of course, the best gains are long gone.
But it’s a whole different story for the “early-in” folks.
For example, let’s say on April 1, 2009 you bought into Dendreon. At the time, it was just a fledgling cancer treatment company. Few had even heard of it.
But what if you had already known about this company?
And what if you had reason to believe they were about to announce positive results from a key clinical trial?
You would’ve been sitting pretty as its stock shot up from $4 to $22 in less than four weeks.
A $5,000 stake would have turned into over $25,000 practically overnight, for a 450% gain in less than a month.
Or take a look at what happened to Generex Biotechnology…
Imagine if you’d gotten inside word on New Year’s Day of 2006 about a new treatment it had just developed. Further imagine you’d gotten in at under $1 per share.
January brought good news to the company, including a multi-million dollar private placement…
But more importantly, on January 9, the company announced plans to start trials on a new diabetes treatment.
The stock skyrocketed 293% in less than two months. You could have turned $10,000 into nearly $30,000.
And then there’s Human Genome Sciences. For months, its stock sold at around $2.50.
But that all changed on July 20, 2009, when it announced positive results for its experimental lupus treatment.
It jumped from $2.50 to $13.84 in a week. That’s a remarkable 453% gain in just seven days.
Now, just to illustrate a point, let’s take it one step further…
Imagine if you invested $10,000 in Dendreon in April and cashed out your $55,000 later that same month.
And let’s say you then reinvested that in Human Genome Sciences in July and cashed out in August.
From a grubstake of $10,000, you’d be sitting on nearly $250,000 – in just four months.
Of course, not every medical breakthrough yields results like these. And no one’s timing can always be “just right.”
But here’s the key point: When a biotech company releases major news, it’s a recipe for the biggest (and fastest) gains possible in the stock market.
And the Cures on Demand breakthrough we’re looking at here is far more powerful than any single drug or “point” solution.
In fact, it’s an event unlike anything to go public in the century-long history of modern biotechnology.
Because it could instantly drive the $956 billion drug industry light years ahead of where it stands today.
Here’s why…
They’re Closing the Books on Pharma’s Trillion-Dollar “Wild Goose Chases”
From Hippocrates… to Madam Curie… right on up to today’s most advanced research labs… Drug discovery has pretty much been the same old story.
Years, sometimes decades of trial and error, billions of dollars spent…
And 999 out of 1000 times, it’s all for naught.
A recent Forbes study showed that Eli Lilly spends about $4.5 billion in research and development (R&D) overall, for every new drug they actually bring to market!
GlaxoSmithKline is even worse, at $8.1 billion…
And AstraZeneca takes the cake, burning through a mind-boggling $12 billion per “success.”
“At $12 billion per drug, inventing medicines is a pretty unsustainable business,” says Forbes biotech expert, Matthew Herper.
“But,” Herper adds, “If a drug company could promise to invent new medicines for [millions instead of billions], its stock price would soar like Apple’s.”
And that’s exactly what this Cures on Demand technology is primed to do.
The days of billion dollar hunts for needles in haystacks are about to end.
Thanks to one company, it’s as if we now have a GPS that instantly zeroes in on exactly where the needle is hidden.
The Supercomputer That’s Saving Lives and Creating Fortunes
So how exactly does this “Cures on Demand” breakthrough work?
It starts with the people…
This company has spent the past 10 years developing an elite team of research scientists to beat any in the world.
It recruited only the “best of the best” from top-secret government technology programs, and leading schools such as MIT and Stanford.
Then they added the hardware…
It’s spent over $100 million building a massive computing system, including terabyte-sized databases and ultra-powerful parallel computers.
Finally came the greatest power of the Cures on Demand system…
In short, this company’s created a computerized version of the human cellular system… down to each molecule.
They’ve “taught” it everything there is to know about protein databases… gene mutation behavior… RNA splice variants… and much, much more.
If there’s any information on the planet Earth concerning human cell behavior, it’s been built into this system.
In other words, this supercomputer leaves nothing to chance.
But what happens next is where the real magic takes place…
This company’s scientists feed in the chemical and biological traits of a disease.
The human cell simulator then creates billions and billions of “virtual” drugs to try to fight the disease.
For each drug, it calculates how fast it would act.
It analyzes how effective it would be.
It figures out side effects, both good and bad.
It then rejects billions of these possibilities.
And narrows down the possible cures to a dozen or so “winners.”
They’ve just accomplished in days or hours what used to take years or decades.
The system has successfully figured out exactly what drug compound or treatment will let human cells beat a malady.
And done it in an incredibly short amount of time.
Obviously, this is huge. But how huge?
What Once Dragged on for Decades, Could Now Rush Through in Months
Consider this: A Federal Trade Commission study reports “For each drug approved by the FDA, a company typically screens between 5,000 and 10,000 compounds.”
That’s a “success” rate of between .0001% and .0002%.
It’s no wonder developing drugs costs nearly $10 billion for every winner.
Until now, highly paid doctors and scientists have done all the work by hand, and at a snail’s pace.
Discovery Magazine pegs development time at a mind-boggling average of nine to 12 years.
But that’s all about to become history.
Instead of taking years or decades, this screening process could now take just weeks… days… maybe even minutes.
That means hundreds of new, proven drugs every year.
Best of all?
This isn’t some pipe dream prediction. Everything I’m talking about is already proving to be true.
One Out of Every Four Drugs Work… Rather Than One in 10,000
In one recent experiment, the company set up its system to search for special molecules that play a major role in treating cancer and many other diseases.
Specifically, they were on the hunt for what doctors call “G-protein-coupled receptors.” These determine how various chemicals interact with the human immune system.
The Cures on Demand algorithm generated 33 different molecule “blueprints.” The company then had its doctors create these actual molecules in a laboratory.
An astonishing eight out of the 33 produced the desired result.
In other words, almost 25% of its predictions were correct!
Compare that to previous methods, where success is often literally a “one in a million” shot.
As the MIT Technology Review recently reported, “The drug discovery business is going through tough times. Drug candidates aren’t moving through the pharmaceutical industry’s pipelines fast enough.”
So just consider how much money a company could save if they only had to test 33 compounds instead of 10,000…
And how much would they pay for access to that technology.
I’m sure you can see why this is such a gigantic leap forward.
And here’s what’s even more amazing about the Cures on Demand system…
Its “Competitive Moat” Keeps Growing
With each simulation, the company uses the results to fine-tune its databases and algorithms even more precisely.
That means every new version of their system gets better and better.
Just look at what Johns Hopkins professor Raimond Winslow had to say in a November 2012 research paper…
“By using computer models,” he said, “potential therapies can be tested at high speed. The results can then be used to guide further experiments to gather new data to refine the models until they are highly predictive.”
And in the meantime, no other company is even close to creating a system like this one has.
Experts have described the creation of a true human cell simulator as “like trying to assemble a jigsaw puzzle using billions of pieces that come from two different puzzles.”
But now they’ve succeeded.
Of course, plenty of testing and trials remain before any drug can be labeled a success. You don’t play fast and loose with human lives, no matter how promising the news.
Yet here’s the key point…
The company is about to pioneer a massive shift from drug discovery by trial and error, to drug discovery by instant creation.
And for investors?
Well, consider just one area of medicine it’s about to revolutionize…
“The Next Frontier” In the Treatment of Cancer
In the Treatment of Cancer According to the National Cancer Institute, the three most prevalent cancers in America are breast, lung and colon cancer.
Sadly, doctors diagnose more than 100,000 new cases yearly for each.
Broken down, lung cancer is the leading cause of cancer-related deaths in the United States, with more than 150,000 each year.
Colon and breast cancer are ranked No. 2 and No. 3, with more than 40,000 deaths annually for each.
That’s a huge toll on humanity.
But bottom line, anything that can be done to lessen these tragedies can be huge for investors, as well. That’s because battling cancer is big business.
In 2012, the four biggest cancer-fighting drugs alone exceeded $9 billion in sales.
Novartis’s Gleevec (leukemia) brought in $1.5 billion…
Genentech’s Herceptin (late-stage breast cancer) generated $1.6 billion…
…
And then there’s Rituxan, the granddaddy of cancer drugs. It generated $3.3 billion last year.
But here’s what most people don’t know: These multi-billion dollar drugs have had very limited medical success.
According to Steven Rosenberg, chief of surgery at the National Cancer Institute, “While these drugs are a big business for companies, most have shortcomings as medicines.”
But some early studies of the new Cures on Demand cancer-fighting drugs are already indicating unprecedented, lasting responses – and a possible cure of metastatic disease.
Dr. Richard Williams from the Imperial College of London says flat out, “These preliminary results are very impressive.”
No wonder this class of drugs has been termed “the next frontier” in the treatment of cancer.
And here’s what’s important to keep in mind…
Unlike the “single-cancer” medications above, doctors could soon harness the unique technology behind this company to help treat virtually every type of cancer… and with unprecedented effectiveness.
That’s huge, considering that Americans spent $23.2 billion on oncology drugs in 2011…
And it’s forecast that by 2015, the kind of drugs this company is working on will be a $64 billion business.
But developing cancer-fighting drugs is just the start.
Slashing Healthcare Costs… And “Its Stock Price Could Soar Like Apple’s”
Practically every day, you’ll find drugs and medicine at the forefront of not just the health news, but business news as well.
It’s not surprising…
Overall, U.S. drug spending in 2010 included $18.2 billion on psychiatric medications… $19.6 billion on diabetes… $20.1 billion on lipid regulators… and $21 billion on respiratory problems.
All told, it adds up to a mammoth $956 billion dollars spent on drugs annually worldwide.
To put that into perspective: That’s more than the entire GDP of Kuwait… Hungary… and Portugal… Combined.
Yet the treatments we have, despite all this money, still are not effective.
And one of the major reasons is the 10-year average it takes to roll out each new drug.
You see, even the most effective drugs generally only work for a small percentage of patients. If you want to cover everyone, you need many drugs, even for a single condition.
Yet each one costs a fortune… And it takes forever to develop.
Just take a glance at the chart on the right.
It shows the number of drugs approved per $1 billion dollars of R&D spending.
The chart covers the past six decades.
As you can see, new drug discovery is getting less efficient as time goes by.
In other words: This situation is getting worse by the day.
The “low-hanging fruit” is long gone, making traditional trial-and-error discovery a losing game.
So think about it…
If you’re a huge $30 billion company and you need a specific new drug, are you going to start working on that the same way you’ve always done…
With big teams of doctors developing 10,000 possible treatments by trial and error?
Or are you going to turn to a company that in a few days can narrow it down to less than 50?
It’s a no-brainer…
But here’s the kicker. It’s the reason why we consider this to be one of the best investment opportunities we’ve uncovered in over 25 years.
Here’s why we believe this company’s stock is destined to “soar like Apple’s.”
Because this company’s “low-risk, big-reward” plan for making money is, in its own way, as brilliant as the Cures on Demand technology itself.
Make Money Every Time Someone Takes a Pill
The executives at this company are pretty darn smart. We know that from meeting with them extensively over the past three years.
They could have made their system available to big pharmaceutical firms, collected a one-time fee for their services, and been on their way.
And sure, they would have made some money that way.
But they know their technology is one-of-a kind. And they know just how much it’s going to save certain companies…
Billions of dollars each.
So the executives asked for something bigger in exchange for their services.
When a company uses the Cures on Demand system to create a drug, this company will now become a part-owner of that drug.
That means each and every time the drug gets prescribed out in the marketplace, they will receive a royalty.
I don’t have to tell you how profitable that will be…
The next time a company like Bristol-Myers Squibb comes up with another $60 billion drug like Plavix…
Or Abbott creates an $8 billion a year drug like Humira…
This company is likely to collect billions and billions in royalties.
Better yet, it doesn’t have to do any of the “dirty work”.
It doesn’t have to worry about getting the new drug to market… Selling it to doctors and hospitals… Or marketing it to prospective patients.
Rather, they just sit back and collect their royalties while Big Pharma does all the hard work.
That’s the power of having a technology that nobody else has access to.
Best of all, this isn’t some harebrained prediction, or something that will happen many years down the road.
The deals are starting to happen right now… this very minute.
Ready to Explode in 2013…
In just the early days of this technology, this company has already signed licensing agreements with some of Pharma’s most serious players, including Biosite, Medarex, Ortho-Clinical Diagnostics and Roche.
Those companies are responsible for some of the biggest-selling drugs in the world, including Mabthera, Lucentis and Epogen.
Yet that’s just the beginning.
Once this company starts bringing in royalties from all these types of big-dollar drugs, the only result is likely to be a sharp and prolonged jump in company revenue… and the stock price.
How high could it go?
There’s no reason this company won’t soon be involved in 10% of the $95.6 billion drug market.
And let’s say they collect just a meager 5% royalty on that $95.6 billion dollars. That’s over $4.7 billion a year.
Right now this company is tiny, with a market cap of just $200 million, and shares trading at around $5.
So $4.7 billion a year in new revenue would instantly multiply the company’s value by a double-digit factor!
The stock could easily jump from $5 to $30 or more. And turn less than $2,000 into more than $10,000, in a heartbeat.
Bottom line…
This company uses its high-tech breakthroughs and genius scientists to figure out the best potential cures. Then someone else does all the work while it shares in the profits.
Here’s your chance to become a “partner” in this windfall.
Imagine making money nearly every time someone gets an injection… applies a lotion… or swallows a pill.
And now there’s a breaking development we’ve just been tipped off about first-hand.
It’s the final key we believe is going to send this company’s shares through the roof.
Serious Research Targeting Serious Returns…
Before I give you the details on the breaking news about this company’s stock, I should explain why we’re so confident about this pick.
It’s this reason that’s led to some of the biggest and fastest gains we’ve seen in previous biotech stocks…
Like 128% on Siga Technologies in little over a year… or 211% on PharmAthene in less than 5 months…
I’m talking about Marc Lichtenfeld.
He’s the Associate Investment Director here at The Oxford Club.
As a financial analyst, Marc’s been written up in publications including The Wall Street Journal and TheStreet.com, where he was a Senior Columnist.
Marketocracy – a leading research company that evaluates the investment industry – ranked his biotech recommended portfolio in the top 1% for five year performance.
Marc has spent the vast majority of his working days investigating high-return opportunities in the biotech, healthcare and technology markets.
His Rolodex reads like a “who’s who” of the healthcare industry: drug company executives… pharma industry insiders… hedge fund managers…
And his ears-to-the-ground research has made his readers some very large amounts of money. For example…
- Marc met with the CEO of Siga Technologies, a vaccine producer, in a suite at the Westin St. Francis hotel in California. Based on the intelligence he uncovered, he soon afterwards recommended the stock to his readers. In a little over a year, he closed out the position for a 97% gain.
- A Chief Operating Officer contact in the industry gave Marc critical insights regarding the management of Nektar Therapeutics, a biopharmaceutical firm. Just seven months after then recommending it to his subscribers, reader Jerry Hammond wrote: “You asked how I did on NKTR. I bought 4000 shares at $4.85 and sold them at $8.80. I will take that anytime.” Reader Bob Whitfield added “I bought NKTR at $4.06 and sold at $8.90, so I got a double.”
- Again, Marc obtained some special intelligence on innovator Delcath Systems, which fights liver cancer, from a Pharma CEO. His subsequent recommendation produced triple-digit-plus returns. Reader Brian Newman said “I sold half my position of DCTH and made a 128% profit. I trust your recommendations.”
The great thing about these gains, and the biotech sector in general, is it didn’t take options or anything fancy to generate real triple-digit returns – in less than a year.
All it took was Marc pinpointing an unusual biotech firm that came up with a new breakthrough technology.
To find these kinds of companies, however, you can’t simply sit behind your desk picking stocks by surfing the internet or reading the newspaper. You have to get out in the real world.
And this current Cures on Demand situation is the perfect example…
Dinner With the Chairman
Marc likely knows more about this company and its breakthrough product than any other analyst in the world.
He recently flew 2,563 miles on Virgin America to personally meet with company executives.
The press was not invited. In fact, almost no one was.
Just the two largest shareholders, the top company executives, and Marc.
They met over dinner at San Francisco’s prominent Orchard Garden Hotel.
They discussed the latest developments with the “Cures on Demand” system.
He heard all about this company’s upcoming collaborations… new strategic alliances… added development capabilities… additional new platforms… even new discoveries.
And now, Marc’s full report on this breakthrough (details below) will show you exactly how to get in right away… for the biggest return in the shortest amount of time.
As Marc explains, there’s never been a better time to get into this company… and the healthcare and biotech sectors as a whole.
The Biggest Blockbuster of 2013
Why healthcare? And why now?
Simple really.
We’re looking at a market about to be flooded with over 65 MILLION newly-minted buyers – the graying baby-boomers.
That’s enough new buyers to fill a city the size of Pittsburgh every month… for nearly the next two decades running.
And if that weren’t enough… it’s not just boomers turning 65…
The number of Americans living to 90 and beyond has tripled in the last three decades, according to a recent Census Bureau report.
“Increasingly, people are living longer,” says demographer Wan He.
Obviously, this generation is going to keep spending on treatments, like the $3.8 billion they’ve put into Crestor (to treat cholesterol) each year…
And the $6.5 billion they pay per year for Humira (for anti-inflammation)…
And the $7.8 billion they’ve spent on Advair (asthma).
But guess what happens when newer, far more effective drugs become available in the coming months and years.
This company will be there to collect royalties on a very serious piece of the billions spent.
That’s why Marc and the entire Oxford Club team have never been more bullish about the potential of the healthcare market than right now…
And, in particular, about the company I’ve been telling you about…
The one company Marc believes will be the biggest blockbuster of 2013.
And that’s why I would like to extend a special invitation to you…
How to Turn This Into Your Own Windfall
Marc’s always on the hunt for the next businesses that not only help people live healthier, longer lives… but also make investors very wealthy in the process.
And with the situation coming up right now, time is of the essence.
So we’d like to share this research with you as soon as possible.
And Marc’s full report, “How to Get Rich From the Cures on Demand Windfall,” will show you how to get in right away, for the biggest return in the shortest amount of time.
We’ll go over everything Marc has uncovered about this company…
The timeline, the technology, the potential risks and rewards…
And of course, the identity and ticker symbol of this company, which he believes could make early shareholders very wealthy.
It’s all part of your welcome to Marc’s trading research service, Healthcare Profits Alert.
The Planets Are Perfectly Aligned Right Now
The idea behind the Healthcare Profits Alert service is simple: to uncover the biggest profit opportunities coming from the exploding healthcare industry.
Because as Oxford Club Investment Director Alexander Green says, “The planets are perfectly aligned for healthcare right now.”
As they’ve analyzed the markets in recent months, both Alexander and Marc have no doubt: Healthcare will be one of the top sectors to invest in for the foreseeable future.
So we’ve come up with a way for our members to take advantage of the urgent, aggressive opportunities in this sector… and a way to capture the greatest profits.
Marc’s 17 years of experience in the field make him the ideal leader for his new Healthcare Profits Alert service.
After all, in recent years, he’s led subscribers to impressive gains with investments in his other recommended portfolios, including…
And you’ll be in good company.
According to a recent Fidelity study, nearly half of American millionaires say they expect to acquire pharmaceutical and healthcare stocks in the near future.
They realize that with 10,000 baby boomers turning 65 every day, the healthcare markets are poised for one of the biggest spending jumps in history.
And right now at The Oxford Club, we’re on the long side of that tidal wave of cash.
With Marc’s new report, “How to Get Rich From the Cures on Demand Windfall,” we’ll show you how to start collecting the biggest gains in the shortest amount of time.
It’s yours the moment you join us and take a subscription for Marc’s service, Healthcare Profits Alert.
“My $4,640 became $17,280 (272.4%) in less than a month.”
With Healthcare Profits Alert, you’ll get research, insight and recommendations on up-and-coming companies…
Intelligence you can’t possibly get from any other investment research service or broad-market “guru.”
As Marc says himself, “Nothing can make you richer, faster, than when a little known company develops a breakthrough drug.”
Problem is, finding that company can be a minefield.
That’s where Marc’s institutional quality research comes in.
He talks to the players. He travels to the company.
He interviews the sales reps, the CEOs, the production people, company executives, even workers on the floor.
He interviews executives at competing companies.
He talks to industry and sector experts.
He talks to his Wall Street contacts – boardroom members, CEOs, fund managers, floor traders – just to get a sense for the market.
Next comes months and months of hardcore research. That’s where he spends thousands of hours poring over scientific papers, medical journals, industry reports, industry statistics, commentary, blogs…
Anything that will help him better understand the product, the market and the potential for the product.
Only when it all adds up, does Marc issue a recommendation.
And Marc’s proud of the tremendous returns those recommendations have brought to his regular readers in the recent past.
For example, Healthcare Profits Alert readers have recently written Marc to say…
- “I am up over 80%.”
- “I’ll gladly take the near-60% gain in any four-month period.”
- “Logged 56.81% in my wife’s Roth IRA account.”
- “I got in at $35.50 and still hold it today at $60 and change, which gives me a 70% gain so far.”
- “My $4,640 became $17,280 (272.4%) in less than a month.”
Yet Marc tells me the opportunities from this coming “Cures on Demand” company stand to eclipse – by far – even his most successful previous recommendations.
You’ll get all the details in our new report, “How to Get Rich From the Cures on Demand Windfall“.
We’ll show you how to start collecting the biggest gains in the shortest amount of time.
And you’ll get plenty of high-upside opportunities to do so…
A $7 “Swing for the Fences”
Since you’ve read this far, I think you’ll be interested in other breaking opportunities Marc’s looking at right now.
Urgent Profit Opportunity #2: “The Misunderstood Cancer Fighter”Euripides said, “You can judge a man by the company he keeps.”
Marc believes you can also judge a small biotech by the “company it keeps.” In other words, by digging down and looking at just who’s investing in a promising outfit.
Marc’s got his eyes on a firm that just received unexpectedly fast FDA approval for a new leukemia treatment.
Many patients taking the most popular current treatment eventually develop a resistance to it. But switching to this new “second” drug showed remarkably effective results in trials – even though 94% of the patients had already failed to improve with two other treatments.
Yet here’s what most on Wall Street simply don’t understand…
Considering its performance as a “second-line” attack on leukemia, this new drug is likely to be just as successful in becoming the first line of treatment.
As a result, Marc’s research shows it could generate up to $1.5 billion in annual sales for this $3.3 billion biotech.
And the “company” this small drugmaker is keeping?
The Baker Brothers – an extremely successful duo who invest primarily in the biotech sector, and have an excellent track record – own nearly six million shares.
And it doesn’t hurt to note that the company’s CEO owns over two million shares, as well.
When you join Marc’s new research service, you’ll get all the important details on this play.
Marc estimates this “Misunderstood Cancer Fighter” could soon grab a hefty chunk of this $4 billion-plus market.
And early investors could see a 200%-plus return.
Urgent Profit Opportunity #3: “The Billionaire’s DNA Pick”Just a few years ago, sequencing the human genome cost millions of dollars.
It will soon cost $500.
As a result, it’s likely that within a decade, the process of having your DNA read and analyzed will be as routine as getting your cholesterol checked.
There are many exciting uses for gene sequencing.
For example, during the recent E. coli outbreak in Germany, scientists were able to read the DNA of the bacterium to figure out which antibiotics would work against it. Doctors will soon do the same to try to fight cancer mutations… and for that matter, treat practically every major health issue you can think of.
And one company is leading the way with its dramatically smaller and far cheaper machines. Thanks to this technology, its gene sequencing now takes less than a day… and soon will only take a few hours.
They’ve also developed a unique sequencer that analyzes samples with very low amounts of DNA. This will unlock hundreds of thousands of archived research samples from around the world.
The company’s stock is trading at just around 12 times expected earnings. That compares with its main competitor, which is at nearly 28 times projected earnings.
Yet this company has far better products and is a cheaper stock. No wonder the board of directors recently authorized a $750 million share buyback.
Billionaire hedge fund manager John Paulson apparently agrees. He now owns 13.5 million shares, making it his fourth-largest stock holding.
As Marc says, “This is very exciting stuff that should pay off huge in the future. I think Paulson is going to make a ton of money in this, and you could too.”
Urgent Profit Opportunity #4: “A $7 ‘Swing for the Fences’ Play”You’ve seen how the healthcare sector can hand you huge gains in lightning speed.
Yet following this market with Marc also has another terrific benefit: You’ll be among the first to learn about amazing new companies, drugs and technologies that have the potential to save people’s lives.
Right now, Marc has just such an opportunity in his sights. And it could make you a ton of money too.
This firm is turning heads with its game-changing treatment for the most aggressive forms of breast cancer. In a recent study, 33% of late-stage patients saw positive results, versus 0% for chemo.
On top of that, this company also has a brain-cancer drug in phase II and phase III trials. So far, these results have been outstanding.
Marc believes this company will soon partner with a larger drug or biotech company that would likely pay a lot of money for these drugs. Its stock – now trading around $7 – could see breathtaking gains.
This is a high-risk/high-reward play. But Marc expects investors to experience the latter.
As a subscriber to Marc’s Healthcare Profits Alert service, these three opportunities – not to mention the Cures on Demand breakthrough – are just the beginning of the research and investment intelligence you’ll receive.
However, I’m going to politely caution you: Once you’ve reviewed Marc’s research, you must be prepared to act quickly and decisively.
The biggest gains will only be available for those who act quickly.
Here’s why…
Realistic Opportunities to Multiply Your Wealth
This is serious research. Marc doesn’t just scan the markets or read over financials.
While the mass media is handing you rehashed press releases, Marc more likely just got off the phone with a company’s Chief Scientific Officer.
When Wall Street waits to find out the news on a potential medical breakthrough, Marc’s sources probably just told him they’re now headed for the FDA’s fast track.
And when the talking heads on CNBC are gushing about the hottest “new” biotech, Marc’s readers have long been sitting on the fattest gains.
In short, what Marc does is separate the wheat from the chaff, the signal from the noise.
Given his remarkable track record, it’s not surprising that lots of major investment firms and professionals rely on Marc’s research.
And some of these folks handle some very serious money. That includes:
Remember, when small healthcare companies develop innovative products… The returns for early shareholders can be mind-boggling.
For example,
- Amgen developed a breakthrough drug in the late 1980s called Epogen to treat kidney problems. To date, Amgen has soared an astronomical 17,677%.
- In July of 1998, Celgene released Thalomid, a leprosy treatment, and in March of 2006, the drug was re-released as a blood cancer treatment. Since its initial release, shares have risen as much as 2,299%.
- And in the early 1990s, Medtronic was trading for an adjusted price of less than $2.00 per share. But thanks to their innovative development of the PCD heart defibrillator in 1993, shares have climbed as much as 1,795%.
These were all remarkable advances, no doubt.
But what Marc foresees in the months ahead stands to blow everything else out of the water…
It all starts with the amazing little company behind Marc’s new research report, “How to Get Rich From the Cures on Demand Windfall.”
Yet there’s so much more…
Here’s What You Get As a New Member…
When you sign up for the Healthcare Profits Alert, you could begin booking windfall gains almost immediately.
That’s because you’ll be one of the very few people with access to Marc’s powerful market insights and recommendations.
Here’s what you can expect:
This should give you everything you need to make thousands of dollars to supplement your income, grow your retirement portfolio, or just enjoy some extra spending cash.
So how much could such a profit-generating service cost?
One Year Paid in Just a Few Weeks
If you accept this offer today, you can get an entire year of Healthcare Profits Alert for just $4,995. A terrific value when you consider the thousands of hours of research and analysis that go into producing these big winners…
Not to mention the oversized returns our recommendations have produced year after year.
Consider, just $5,000 in each of Marc’s recommendations on PharmAthene, Immunogen, and Adolor would have handed you profits of over $15,000…
It’s this level of sustained profitability that’s made Marc one of the most popular editors amongst our members. Just take a look at what Marc’s subscribers have to say…
“I’m now up $7,700. You made me a wiser investor.”
Kevin Rice says, “I’m now up $7,700. Before joining you I was a pure gambler. You changed my mentality and made me a wiser investor.”
Jesse McCray told Marc, “Following your advice, I made slightly over 100% on Delcath Systems. I really like the concise, easy to understand way you write your email alerts. Keep up the good work!”
Paula Simpson wrote in to say, “I am glad I made the right move and cashed out my entire position making a 159% profit. Thanks!”
Perhaps George Demare put it best: “I made a bit over $10,000 in a single investment following your recommendation. My gain was not only financial, I now know about this great little company that is developing an amazing medicine that well may save the lives of millions of cancer patients. How brilliant!”
You can see how having an experienced and successful market analyst in your court can truly change your financial future.
There will never be a better time to sign up for an entire year of Healthcare Profits Alert than right now.
Any one of Marc’s coming recommendations could have a profound impact on your wealth in the coming year.
We’re onto the biggest investment opportunity of 2013 – the tiny Cures on Demand company about to explode…
Not to mention the “Misunderstood Cancer Fighter” he believes will spark 200% gains… the gene-sequencing innovator that has a billionaire hedge-fund manager practically drooling… and the tiny biotech whose $7 stock could soon deliver astronomical returns.
And the biggest investment opportunity of the decade – healthcare.
My Promise to You
Explosive short-term profits aren’t for everyone. We understand that.
That’s why Marc’s publishers at The Oxford Club have agreed to give you 60 days to try out Healthcare Profits Alert.
Use this time to test out this new service… Paper trade each move if you like… And see if you aren’t completely blown away by the results.
If at any time during those 60 days you feel for any reason Healthcare Profits Alert isn’t for you, simply call, write, or email us for an immediate refund. (Less our customary 10% processing fee.) There’s absolutely no additional risk in trying it.
And, you get to keep Marc’s new research report, “How to Get Rich From the Cures on Demand Windfall.”
Think about it…
Get These Winners By Registering Now
Today you can.
Get in on these coming waves of double- and triple-digit winners, over and over again, all for just $4,995.
Just click here to register right now in less than three minutes.
Or if you prefer, call our Member Services Department at 888.570.9830 or 410.454.0498 and mention Priority Code WTOTP301 and we’ll process your order in person.
And as you can see, by acting right now, you get two great benefits here:
First, you will immediately step to the forefront of the most powerful investment trend of the coming decade… starting with the breakthrough Cures on Demand play…
And second, you’ll enjoy limited risk by simply trying Healthcare Profits Alert for 60 days… and even if you should cancel, keep all of the research you’ve received…
I think you’ll agree that makes this a wise and risk-free decision.
To claim your charter membership to Healthcare Profits Alert and one-time only discounted price, click here.
I look forward to having you onboard.
Sincerely,
Jeff Yastine
Editorial Director, The Oxford Club
February 2013
So click here to get in now, before it’s too late.
P.P.S. One more reminder: Stock prices of the hottest healthcare companies can move fast – particularly if word of the company’s new products or test results leak out.
It happens all the time. And I would hate for you to miss out on any of these opportunities.
So make sure to register for Healthcare Profits Alert right now, and get instant access to Marc’s new research report, “How to Get Rich From the Cures on Demand Windfall,” as well as his entire open portfolio of recommendations.